Identification | Back Directory | [Name]
Evogliptin hydrochloride | [CAS]
1246960-27-9 | [Synonyms]
DA1229 DA-1229 DA 1229 Evogliptin HCl Evogliptin hydrochloride | [Molecular Formula]
C19H27ClF3N3O3 | [MOL File]
1246960-27-9.mol | [Molecular Weight]
437.89 |
Hazard Information | Back Directory | [Description]
Evogliptin, also known as DA-1229, is a potent and selective DPP4 inhibitor (dipeptidyl peptidase 4 inhibitor). Evogliptin improves insulin resistance and delays the onset of diabetes. Evogliptin improves the insulin sensitivity in HF mice and delays the onset of diabetes in young db/db mice. DA-1229 monotherapy (5 mg for 12 weeks) improved HbA1c, fasting plasma glucose level, OGTT results and β-cell function. This drug was well tolerated in Korean subjects with type 2 diabetes mellitus. |
|
Company Name: |
Lynnchem
|
Tel: |
86-(0)29-85992781 17792393971 |
Website: |
http://www.lynnchem.com/ |
Company Name: |
Novachemistry
|
Tel: |
44-20819178-90 02081917890 |
Website: |
https://www.novachemistry.com/ |
Company Name: |
BOC Sciences
|
Tel: |
16314854226 |
Website: |
www.bocsci.com |
|